Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.

Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption, post injection, to enable more effective management of blood glucose levels.  This is to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypo and hyperglycaemia.

The double-blind, randomised, three-way cross over Phase I clinical study compares the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments. The trial has been conducted in Austria at an internationally recognised centre of excellence in the field of diabetes research and preliminary results are expected in Q4 2019.

Sarah Howell, Chief Executive Officer at Arecor, said: "The completion of the AT247 Phase I clinical trial is an important step in our strategy to develop even faster acting insulins targeted at improving treatment and healthcare outcomes for people living with Type I diabetes.  I look forward to reporting the headline data from this Phase I study in due course, the first product in our proprietary development pipeline.”

 

For more information, please contact:

 

Arecor Limited

www.arecor.com

Dr Sarah Howell, Chief Executive Officer

Tel: +44 (0) 1223 426060

Email: sarah.howell@arecor.com

 

 

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: susan.lowther@arecor.com

 

 

Mo PR Advisory

www.mopradvisory.com  

Mo Noonan

Mob: +44 (0) 7876 444977

Email: mo@mopradvisory.com 

 

 

 

 

Notes to Editors

 

About Arecor

Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market.  Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.  Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

 

ArestatTM is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides.  Arecor’s proprietary products leverage ArestatTM to enable improved treatments for diabetes including an ultra-rapid acting insulin for Type I diabetes and an ultra-concentrated (up to 100U/mL) rapid acting insulin, as well as a portfolio of undisclosed pre-clinical candidates.  Our clinical programmes are significantly de-risked because we reformulate existing approved products with known safety and efficacy profiles. 

 

For our partners, we use ArestatTM to deliver superior reformulations of their proprietary products, which would otherwise not be possible.

 

For further details please see our website, www.arecor.com

 

 

Compliance with GDPR

You have been sent this email, as an individual who has expressed an interest in Arecor Limited. Please see our privacy policy at www.arecor.com/about us/ Privacy Policy concerning the processing by Arecor of your personal data. Your personal data is retained by Arecor and is not accessed by or transferred to anyone outside Arecor, save only where the database may be maintained by a third-party processor for and on behalf of Arecor.

Arecor Limited processes personal data only with your consent.

Should you wish to withdraw consent to any further processing of your personal data by Arecor please reply to this email and type “UNSUBSCRIBE” in the ‘subject line’.

 

If you have any queries, please email our Chief Data Officer: dataofficer@arecor.com